Last reviewed · How we verify
Xeroform
Xeroform is a Small molecule drug developed by Precisio Biotix Therapeutics, Inc.. It is currently in Phase 1 development. Also known as: Kenacomb.
Xeroform is a dressing used in the treatment of various conditions, including nail bed injuries, nail lacerations, and burns, as seen in clinical trials on ClinicalTrials.gov. It is also known as 2,4,6-Tribromophenol, a compound with unknown modality according to ChEMBL.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Xeroform |
|---|---|
| Also known as | Kenacomb |
| Sponsor | Precisio Biotix Therapeutics, Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Nailbed Repair for Patients With Nailbed Injuries (NA)
- The Effects of Post-Operative Interventions on Surgical Site Occurrences in AWR (NA)
- RECELL to Promote Healing Following Carbon Dioxide (CO2) Laser Treatment in Cosmetic Patients (PHASE4)
- RES® Prepared With RECELL® Compared to Standard of Care Dressings of Partial-thickness Burns in Ages 1-16 Years (NA)
- RECELL® System Combined With Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction (NA)
- RES Prepared With RECELL® Compared to Conventional Care for Healing of Donor Sites in Ages 1-16 Years (NA)
- Effect of Nitropaste in Chest Masculinizing Surgery (PHASE4)
- Surgical Dressings After Endoscopic Carpal Tunnel Release (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xeroform CI brief — competitive landscape report
- Xeroform updates RSS · CI watch RSS
- Precisio Biotix Therapeutics, Inc. portfolio CI
Frequently asked questions about Xeroform
What is Xeroform?
Who makes Xeroform?
Is Xeroform also known as anything else?
What development phase is Xeroform in?
Related
- Manufacturer: Precisio Biotix Therapeutics, Inc. — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Kenacomb
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing